Table 2 Lab Results for Case 1 and Case 2 during hospitalization(s)
Laboratory Investigations: General | Laboratory Reference Ranges | Case 1 Laboratory Results | Case 2 Laboratory Results |
|---|---|---|---|
Erythrocyte Sedimentation Rate (ESR) | 0–15 mm/hr | 59 mm/hr at presentation; 2 mm/hr 6 months post-treatment | 14 mm/hr at presentation; 2 mm/hr 6 months post-treatment |
C-reactive Protein (CRP) | < 0.5 mg/dL | 12.9 mg/dL at presentation; < 0.5 mg/dL 6 months post-treatment | 25 mg/dL at presentation; < 0.5 mg/dL 6 months post-treatment |
Hemoglobin | 13.0–16.0 g/dL | 7.3 GM/dL | 8.3 GM/dL |
Creatinine | 0.71–1.16 g/dL | 0.98 at presentation | 1.21 at presentation |
Urinalysis | RBC: 0–2/hpf Protein: Negative | RBC > 100/hpf Protein 100 mg/dL | RBC 6–10/hpf at admission; > 100/hpf day 9 hosopitalization |
Protein/Creatinine ratio | 0- < 0.2 | 2.07 | 3.72 |
Laboratory Investigations: Rheumatologic | |||
Anti-Nuclear Antibody (ANA) | < 1:80 | 1:80 | < 1:80 |
Double-Stranded DNA | 0–9 IU/mL | 0 IU/mL | 0 IU/mL |
Complements (C3, C4) | C3: 82–193 mg/dL C4: 15–57 mg/dL | C3: 154 mg/dL C4: 32 mg/dL | C3: 169 mg/dL C4:26 mg/dL |
Anti-Smith | 0.0–0.9 | < 0.2 | < 0.2 |
anti-RNP | 0.0–0.9 | < 0.2 | < 0.2 |
SSA | 0.0–0.9 | < 0.2 | < 0.2 |
SSB | 0.0–0.9 | < 0.2 | < 0.2 |
Cardiolipin IgG | < 20 GPL U/mL | 0 GPL U/mL | 0 GPL U/mL |
Cardiolipin IgM | < 20 MPL U/mL | 0 MPL U/mL | 0 MPL U/mL |
Beta-2-Glycoprotein IgG | < 20 SGU | Not detected | Not detected |
Beta-2-Glycoprotein IgM | < 20 SMU | Not detected | Not detected |
DRVVT | 33–43 seconds | 35 seconds | 38 seconds |
STACLOT | No lupus anti-coagulant detected | No lupus anti-coagulant detected | No lupus anti-coagulant detected |
Anti-glomerular basement membrane antibody IgG (EU) | 0–19 AU/mL | 0 AU/mL | 0 AU/mL |
ANCA profile (during hospitalization) | < 1:20 AU/mL, PR3 0 | C-ANCA pattern 1:640, PR3 812 AU/mL | c-ANCA pattern 1:5120, PR3 1242 AU/mL |
ANCA profile (6 months post-treatment) | < 1:20 AU/mL, PR3 0 | < 1:20 AU/mL, PR3 0 | < 1:20 AU/mL, PR3 0 |
Laboratory Investigations: Infectious | |||
Hepatitis A Antibodies, total Hepatitis A Antibody, IgM | Negative | Negative | Negative |
Hepatitis B Virus Core Antibodies (total) Hepatitis B Virus Core Antibody, IgM Hepatitis B Virus Surface Antibody Hepatitis B Virus Surface Antigen | Negative | Negative | Negative |
Hepatitis C Virus Genotype Hepatitis C Virus Antibody Hepatitis C Virus by Quantitative NAAT | Negative | Negative | Negative |
Bartonella henselae Antibody, IgG and IgM | Negative | Negative | Negative |
Bartonella quintana Antibody, IgG and IgM | Negative | Negative | Negative |
Herpes Simplex Virus (HSV) DFA with Reflex to HSV Culture | Negative | Negative | Negative |
Blood cultures | Negative | 1 of 4 bottles positive for Coagulase-Negative Staphylococcus > 24 hours after collection | Negative |
PCR Respiratory Viral Panela | Negative | Negative | Negative |
AFB Stain and culture: Bronchoalveolar lavage (BAL) | No organisms on gram stain; negative cultures | Negative | Negative |
Fungal stain and culture: BAL | No organisms on gram stain; negative cultures | Negative | Negative |
Bacterial stain and culture: BAL | No organisms on gram stain; negative cultures | Negative | Negative |
Universal PCR: BAL | Negative | Negative | Negative |
Aspergillus antigen Index: BAL | < 0.5 | < 0.5 | 0.55 |
Anti-Streptolysin O | 0–240 IU/mL | 125 IU/mL | 200 IU/mL |
DNAse B | 0–250 U/mL | < 250 U/mL | < 250 U/mL |
Tuberculosis | Negative | Negative | Negative |
Histoplasmosis antigen (urine) | < 0.5 ng/mL | < 0.5 ng/mL | < 0.5 ng/mL |
Histoplasmosis antigen (serum) | 0.19–60.0 ng/mL | Not detected | Not detected |
Human Immunodeficiency Virus (HIV) | Negative | Negative | Negative |